晚期肺腺癌外周血胸苷酸合成酶mRNA水平与培美曲塞疗效的关系

Relationship between thymidylate synthase gene expression and therapeutic effect of pemetrexed in advanced lung adenocarcinoma

目的探讨胸苷酸合成酶基因表达与晚期肺腺癌培美曲塞化疗疗效的关系。方法40例晚期肺腺癌患者接受培美曲塞-顺铂方案化疗,根据胸苷酸合成酶基因表达水平分为低表达组(12例)和高表达组(28例),实时荧光定量PCR检测外周血胸苷酸合成酶mRNA的表达。结果低表达组化疗缓解率显著高于高表达组(58.3%vs.21.4%)(P<0.05);低表达组中位无进展生存时间显著长于高表达组(5.7个月vs.3.6个月)(P<0.05)。结论胸苷酸合成酶mRNA可作为培美曲塞治疗晚期肺腺癌的疗效预测指标。

Objective To explore the relationship between thymidylate synthase（TS） gene expression and therapeutic effect of pemetrexed in advanced lung adenocarcinoma. Methods Fourty patients with advanced lung adenocarcinoma received chemotherapy with pemetrexed-cisplatin regime, who were divided into two groups of L（12 cases, with lower TS expression） and H （28 cases, with higher TS expression）. The peripheral blood was collected for detecting TS mRNA expression by QRT-PCR. Results The remission rate（CR＋PR） was higher in group L than that in group H （58. 3% vs. 21.4%） （P〈0. 05）. The tumor-free survival time was longer in group L than that in group H（5.7 months vs. 3.6 months）（P〈0. 05）. Conclusion TS mRNA expression may be taken as a predictive factor for evaluating therapeutic efficacy of pemetrexed in advanced lung adenocarcinoma.